Skip to main content
Premium Trial:

Request an Annual Quote

Inflammatix: Heiner Dreismann

Immune system molecular diagnostics firm Inflammatix has appointed Heiner Dreismann to its board of directors. He has more than 35 years of experience in the life sciences and healthcare industries and was the CEO of Roche Molecular Systems from 2000 to 2006. Dreismann also held leadership positions at Roche's diagnostic division, and he currently serves on the boards of several public, private, and non-profit organizations.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.